title: The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.
abstract: TMPRSS2:ERG is a gene fusion resulting from the chromosomal rearrangement of the androgen-regulated TMPRSS2 gene and the ETS transcription factor ERG, leading to the over-expression of the oncogenic molecule ERG. This gene rearrangement has been found in approximately half of all prostate cancers and ERG overexpression is considered as a novel diagnostic marker for prostate carcinoma. However, little is known about the role of the TMPRSS2:ERG gene fusion in ovarian cancer. The purpose of this study was to test ERG expression in ovarian cancer and its potential as a diagnostic marker for ovarian carcinoma progression. A tissue microarray containing 180 ovarian cancer tissues of various pathological types and grades were examined by immunohistochemical analysis for expression of ERG. We also used 40 prostate carcinoma tissues and 40 normal tissues for comparison in parallel experiments. ERG-positive expression was detected in 40% of the prostate tumor cancer, as well as in internal positive control endothelial cells, confirming over-expression of ERG in prostate cancer at relatively the same rate observed by others. In contrast, all of the ovarian tumor patient tissues of varying histologic types were ERG-negative, despite some positivity in endothelial cells. These results suggest that the oncogenic gene fusion TMPRSS2:ERG does not occur in ovarian cancer relative to prostate cancer. Therefore, development of ERG expression profile would not be a useful diagnostic or prognostic marker for ovarian cancer patient screening.
authors.affiliation: Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
authors.forename: Lillian
authors.initials: L
authors.lastname: Huang
authors.forename: Isaiah G
authors.initials: IG
authors.lastname: Schauer
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Imelda
authors.initials: I
authors.lastname: Mercado-Uribe
authors.forename: Michael T
authors.initials: MT
authors.lastname: Deavers
authors.forename: Jiaoti
authors.initials: J
authors.lastname: Huang
authors.forename: Jinsong
authors.initials: J
authors.lastname: Liu
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015141:Los Angeles; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000737:chemistry; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D013781:Texas; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D015514:Oncogene Proteins, Fusion; C515553:TMPRSS2-ERG fusion protein, human
references.citation: Cancer Res. 2001 Feb 15;61(4):1686-92
references.pmid: 11245484
references.citation: Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37
references.pmid: 20585344
references.citation: Methods Mol Biol. 2009;487:243-66
references.pmid: 19301651
references.citation: Cancer Res. 2011 Aug 15;71(16):5387-92
references.pmid: 21676887
references.citation: Blood. 2008 Apr 1;111(7):3498-506
references.pmid: 18195090
references.citation: Cancer Cell. 2010 May 18;17(5):443-54
references.pmid: 20478527
references.citation: Mech Dev. 2009 Mar-Apr;126(3-4):220-9
references.pmid: 19027849
references.citation: Genomics. 1997 Sep 15;44(3):309-20
references.pmid: 9325052
references.citation: J Clin Pathol. 2011 Jul;64(7):553-60
references.pmid: 21330315
references.citation: Mol Endocrinol. 2007 Dec;21(12):2855-63
references.pmid: 17636035
references.citation: Cancer Res. 2006 Sep 1;66(17):8337-41
references.pmid: 16951139
references.citation: Nat Genet. 1994 Feb;6(2):146-51
references.pmid: 8162068
references.citation: Cell Cycle. 2010 Sep 1;9(17):3457-9
references.pmid: 20814243
references.citation: Neoplasia. 2010 Jul;12(7):590-8
references.pmid: 20651988
references.citation: BMC Cancer. 2008 Aug 11;8:230
references.pmid: 18694509
references.citation: J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86
references.pmid: 9839517
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10
references.pmid: 18245377
references.citation: Nat Rev Urol. 2009 Aug;6(8):429-39
references.pmid: 19657377
references.citation: Nat Rev Cancer. 2008 Jul;8(7):497-511
references.pmid: 18563191
references.citation: Cancer Biol Ther. 2007 Jan;6(1):40-5
references.pmid: 17172822
references.citation: Oncogene. 2007 Jul 5;26(31):4596-9
references.pmid: 17237811
references.citation: Eur J Gynaecol Oncol. 2004;25(2):157-63
references.pmid: 15032272
references.citation: Pathol Int. 2011 Jul;61(7):409-14
references.pmid: 21707844
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Int J Mol Med. 2011 Jul;28(1):109-14
references.pmid: 21503567
references.citation: PLoS One. 2011;6(6):e21319
references.pmid: 21731703
references.citation: Mol Cell Endocrinol. 2010 Dec 15;330(1-2):10-6
references.pmid: 20673788